LNSR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LNSR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. LENSAR's Cash Ratio for the quarter that ended in Dec. 2023 was 2.07.
LENSAR has a Cash Ratio of 2.07. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for LENSAR's Cash Ratio or its related term are showing as below:
During the past 5 years, LENSAR's highest Cash Ratio was 4.79. The lowest was 0.59. And the median was 2.07.
The historical data trend for LENSAR's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENSAR Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Cash Ratio | 0.59 | 4.79 | 3.63 | 1.28 | 2.07 |
LENSAR Quarterly Data | ||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Ratio | Get a 7-Day Free Trial | 1.28 | 0.80 | 2.41 | 2.26 | 2.07 |
For the Medical Devices subindustry, LENSAR's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Cash Ratio distribution charts can be found below:
* The bar in red indicates where LENSAR's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
LENSAR's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Ratio (A: Dec. 2023 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 24.064 | / | 11.632 | |
= | 2.07 |
LENSAR's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:
Cash Ratio (Q: Dec. 2023 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 24.064 | / | 11.632 | |
= | 2.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENSAR (NAS:LNSR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of LENSAR's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Gary M Winer | director | C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826 |
Aimee S Weisner | director | ONE EDWARDS WAY, IRVINE CA 92614 |
Nr-gri Partners Gp, Llc | 10 percent owner | 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116 |
Nr-gri Partners, Lp | 10 percent owner | 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116 |
Todd B Hammer | director, 10 percent owner | NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116 |
Thomas B Ellis | director, 10 percent owner | 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116 |
North Run Advisors, Llc | 10 percent owner | 62 WALNUT STREET, WELLESLEY MA 02481 |
North Run Capital, Lp | 10 percent owner | 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116 |
Staab Thomas R Ii | officer: Chief Financial Officer | C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Kendra Wong | officer: Principal Accounting Officer | C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826 |
Elizabeth G. O'farrell | director | 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451 |
Alan B. Connaughton | officer: Chief Operating Officer | C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826 |
Nicholas T Curtis | director, officer: Chief Executive Officer | C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016 |
Pdl Biopharma, Inc. | 10 percent owner | 59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521 |
Lindstrom Richard L Md | director | 2811 WESTWOOD PL, WAYZATA MN 55391 |
From GuruFocus
By Business Wire Business Wire • 05-24-2021
By Business Wire Business Wire • 02-08-2021
By Business Wire Business Wire • 02-14-2023
By Business Wire Business Wire • 08-16-2022
By Business Wire Business Wire • 05-05-2021
By Business Wire Business Wire • 11-02-2022
By Business Wire Business Wire • 11-12-2021
By Business Wire • 11-02-2023
By Business Wire Business Wire • 08-01-2022
By Business Wire Business Wire • 02-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.